Studies performed by Jeremy N. Rich and collaborators [32] proved the existence of mixed clinical responses of anti-PDGFR-based strategies insisting on the necessity of models of cancers, in order to better develop new cancer therapies. This evidence concerns the gene PDGFRB and cancer.